RxDoctor Payments Data

Farough Kerendi, MD

General Practice · Los Angeles, CANPI 1568538593

Payments from drug & device makers

$322in general payments, 2019–2025

Across 15 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$53
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$48
  • Sun Pharmaceutical Industries Inc.$35
  • Otsuka America Pharmaceutical, Inc.$29
  • Acadia Pharmaceuticals Inc$29
  • AbbVie$28
  • plus $99 from 5 others

What the payments were for

  • Food & beverage$322100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$322 in reported general payments places this provider in the 55th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$302,010
Medicare patients
235
Services billed
3,996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin70$133,913
JanuviaSitagliptin Phosphate180$88,805
AustedoDeutetrabenazine26$88,704
EliquisApixaban182$63,725
QbrelisLisinopril12$31,742
SantylCollagenase Clostridium Hist.35$23,168
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate13$21,962
EntrestoSacubitril/Valsartan28$17,320
TrulicityDulaglutide13$13,145
CreonLipase/Protease/Amylase12$13,115
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog40$12,987
GlatopaGlatiramer Acetate24$12,813
JardianceEmpagliflozin28$12,456
Diclofenac Sodium39$10,952
XareltoRivaroxaban30$10,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$48$133,91370 claims
Teva Pharmaceuticals USA, Inc.Austedo, Albuterol Sulfate$53$90,74350 claims
MerckJanuvia$20$88,805180 claims
AbbVieCreon$28$13,11512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 12,963 general practice providers in California.

Other general practice in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →